HCV Protease Inhibitors in Clinical Practice
16
HCV Protease Inhibitors in Clinical Practice
description
HCV Protease Inhibitors in Clinical Practice. Currently Approved HCV Agents: Telaprevir and Boceprevir. Patient Selection for HCV Triple Therapy. Telaprevir: Recommended Treatment Duration (Weeks). Telaprevir + PEG-IFN- α -2a + RBV for HCV Genotype 1. - PowerPoint PPT Presentation
Transcript of HCV Protease Inhibitors in Clinical Practice
HCV Protease Inhibitors in Clinical Practice
Currently Approved HCV Agents: Telaprevir and
Boceprevir
Patient Selection for HCV Triple Therapy
Telaprevir: Recommended Treatment Duration (Weeks)
Telaprevir + PEG-IFN-α-2a + RBV for HCV Genotype 1
Boceprevir: Recommended Treatment Duration (Weeks)
Boceprevir + PEG-IFN-α-2b + RBV for HCV Genotype 1
Select Predictors of SVR in Chronic HCV Genotype 1 Therapy
Selected Adverse Events
HCV Treatment-related Anemia
Preparing Patients for HCV Treatment
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)